A multi-center, randomized, parallel group, double-blind, placebo controlled proof of concept and dose ranging study with an active control to assess the efficacy and safety/tolerability of UK-369,003 immediate release (IR) and modified release (MR) in the treatment of men with lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED)

Trial Profile

A multi-center, randomized, parallel group, double-blind, placebo controlled proof of concept and dose ranging study with an active control to assess the efficacy and safety/tolerability of UK-369,003 immediate release (IR) and modified release (MR) in the treatment of men with lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Gisadenafil; Tamsulosin
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2010 Planned number of patients changed from 414 to 609.
    • 22 Feb 2010 Results published in BJU International.
    • 23 Apr 2008 Added tamsulosin as an active comparator drug; update from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top